RCC-PDXovo-RenalCellCarcinoma-WXS-unaligned-reads - samples

NIAID Data Ecosystem2026-03-10 收录

肾细胞癌肿瘤异质性

化疗耐药机制

数据链接：

https://www.omicsdi.org/dataset/ega/EGAD00001003590 数据链接链接失效反馈

官方服务：

资源简介：

Ultra-Fast Patient-Derived Xenografts Identify Functional and Spatial Tumour Heterogeneities that Drive Therapeutic Resistance - WXS unaligned readsEGA dataset EGAD00001003590

创建时间：

2017-09-20

Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.. Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.

头颈部鳞状细胞癌基因

化疗耐药机制

In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur

NIAID Data Ecosystem70

Integrative Analyses of Gene Expression and DNA Methylation Profiles in a Breast Cancer Cell Line Model of Tamoxifen-Resistance Indicate a Crucial Role of Cells with Stem-like Properties. Homo sapiens

化疗耐药机制

表观遗传调控

Purpose: Development of resistance to tamoxifen is an important clinical issue in the treatment of patients with breast cancer. Tamoxifen resistance may be the result of the acquisition of epigenetic

NIAID Data Ecosystem50

DataSheet2_Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest.xlsx

化疗耐药机制

代谢重编程

The occurrence of cisplatin resistance is still the main factor limiting the therapeutic effect of non-small cell lung cancer (NSCLC). It is urgent to elucidate the resistance mechanism and develop no

NIAID Data Ecosystem40

Additional file 7: of Association of tamoxifen resistance and lipid reprogramming in breast cancer

化疗耐药机制

代谢重编程

Batch corrected CPM counts of cell lines and patients. (TXT 28313 kb)

NIAID Data Ecosystem60

Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy

化疗耐药机制

IFN-γ信号通路

"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,

NIAID Data Ecosystem40

RCC-PDXovo-RenalCellCarcinoma-WXS-unaligned-reads - samples

资源简介：

相关数据集